Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Generic drug approvals boost pharma firms' global ambitions

By Liu Zhihua | China Daily | Updated: 2019-03-07 11:42
Share
Share - WeChat
Many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. [Photo/VCG]

Chinese pharmaceutical companies are strengthening their presence on the world stage with an increasing number of generic drug approvals from the United States, thanks to rising research and development capabilities and official support for innovation, industry insiders said.

According to statistics from the Healthcare Executive Institute, a leading healthcare industry think tank based in Beijing, as of Dec 24, 2018, Chinese pharmaceutical companies had received 77 generic drug approvals - known as abbreviated new drug applications or ANDAs - from the US Food and Drug Administration.

The number was 38 in 2017 and 22 in 2016. Before 2016, Chinese pharmaceutical companies had fewer than 15 ANDAs approved on average each year.

A recent example is a generic drug made by Qingdao Baheal Pharmaceutical Ltd, a holding subsidiary of Baheal Pharmaceutical Group headquartered in Beijing and Qingdao, Shandong province.

Its generic drug Nida, which is an extended-release tablet containing metformin, a medicine widely used to manage type-2 diabetes, was approved by the USFDA on Dec 27, 2018.

The company announced earlier that the first batch of the drug was about to be delivered to the US market.

The think tank said one reason behind the rise in approvals is that many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. Another reason is that once a generic drug receives US approval, it is automatically seen as having passed China's generic consistency evaluation requirements.

In 2016, the Chinese central authorities issued an opinion on "conducting consistency evaluations of the quality and efficacy of generic drugs", signaling a push for an industrywide overhaul of generic drug quality. Failure to pass the evaluation before the required deadline leads to revocation of the drug title's registration license or ineligibility for government tendering. Besides, if three titles of a generic drug have passed the evaluation, others will not be allowed for government tendering.

Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy, added that the Chinese authorities' recent policies are very supportive of innovation and high-quality generic drug research and development, providing solid incentives for Chinese pharmaceutical companies to file more ANDAs.

"If a Chinese generic drug gains US approval, it is often fast tracked by Chinese authorities when it applies for domestic approval, giving it an advantage in the fiercely competitive domestic generic drug market," he said.

Shen Yaping, vice-president with Jiangsu Hengrui Medicine Co Ltd, a top Chinese pharmaceutical company listed in Shanghai, said the company now files new generic drug applications to domestic and US authorities for this reason.

"Going global and innovation are the two most important development strategies for our company, and now we feel encouraged, because a lot of government policies are inspiring to companies like us that want to expand overseas business," Shen said.

The overseas markets, especially the US, are large and alluring, yet in the past, Chinese pharmaceutical companies lacked the ability to expand overseas, he said, adding that as a number of first-tier Chinese pharmaceutical companies have succeeded in developing overseas business, others are trying to keep up with them.

His company and its subsidiary Shanghai Hengrui Pharmaceutical Co Ltd have received 16 ANDA approvals, according to its website.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 天堂√在线中文最新版8| 久久99热精品免费观看动漫| 久草免费资源站| 久久99精品久久久久子伦| 一级特黄aaa大片在线观看视频| 久香草视频在线观看| 中文字幕被公侵犯的漂亮人妻| 一级国产a级a毛片无卡| 91久久偷偷做嫩草影院免| 黄页网站免费在线观看| 精品少妇人妻AV免费久久洗澡| 波多野结衣在丈夫面前| 日韩精品视频在线观看免费| 成人区人妻精品一区二区不卡网站| 国内精品久久久久久99蜜桃| 国产愉拍精品视频手机| 免费看曰批女人爽的视频网址 | 国产限制级在线观看| 国产午夜电影在线观看| 免费人成激情视频在线观看冫| 亚洲一区二区日韩欧美gif| 中国一级特黄特级毛片| 4480新热播影院| 老湿影院在线观看| 欧美双茎同入视频在线观看| 新梅金瓶1之爱奴1免费观| 国产精品无码免费播放| 可以直接看的毛片| 亚洲gv天堂gv无码男同| www.中文字幕| 青青青手机视频在线观看| 激情内射亚洲一区二区三区爱妻| 日本伊人色综合网| 国产精品无码2021在线观看| 午夜视频体验区| 久久精品道一区二区三区| 99久久精彩视频| 美女的扒开尿口让男人桶动态图| 欧洲成人午夜精品无码区久久| 女房东用丝袜脚夹我好爽漫画| 国产伦精品一区二区免费|